GlassScriptPhysician profile
Rizza Marie Macas
NPI 1578074688
$5,288.04
in general payments reported to CMS, 2019-2025
27 companies · $1,709 in 2025
The $1,709 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $29.67 · 2022: $519 · 2023: $1,368 · 2024: $1,662 · 2025: $1,709.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,281 · Education: $459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,280.69 |
| Education | $458.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $874.60 | 2022-2025 | Cresemba, Xospata |
| Astrazeneca Pharmaceuticals LP | $660.28 | 2023-2025 | Calquence |
| Incyte Corporation | $507.78 | 2021-2025 | Jakafi, Niktimvo |
| Sobi, INC | $475.59 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $376.18 | 2023-2024 | Reblozyl |
| Celgene Corporation | $289.05 | 2022-2025 | Reblozyl, Onureg |
| Lilly USA, LLC | $257.38 | 2023-2025 | Jaypirca |
| Beigene USA, INC. | $224.14 | 2024 | Brukinsa |
| Novartis Pharmaceuticals Corporation | $175.86 | 2022-2025 | |
| Syndax Pharmaceuticals, INC. | $160.00 | 2025 | |
| Pharmaessentia USA Corporation | $153.25 | 2023-2024 | Besremi |
| Janssen Pharmaceuticals, INC | $145.06 | 2022 | |
| Glaxosmithkline, LLC. | $130.11 | 2023-2025 | Ojjaara |
| Janssen Biotech, INC. | $118.80 | 2021-2024 | Imbruvica |
| Abbvie INC. | $110.30 | 2023-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $106.55 | 2023-2025 | Reblozyl, Keytruda |
| Rigel Pharmaceuticals, INC. | $85.11 | 2023-2025 | Rezlidhia, Tavalisse, Gavreto |
| Daiichi Sankyo INC. | $83.36 | 2024-2025 | Vanflyta |
| Teleflex LLC | $68.47 | 2025 | Arrow |
| Blueprint Medicines Corporation | $58.36 | 2023-2024 | Ayvakit |
| Amgen INC. | $54.16 | 2023 | Blincyto, Kyprolis |
| Servier Pharmaceuticals LLC | $49.63 | 2023-2024 | |
| Karyopharm Therapeutics INC. | $28.92 | 2025 | Xpovio |
| Takeda Pharmaceuticals U.S.A., INC. | $26.52 | 2024 | Iclusig |
| Pharmacyclics LLC, An Abbvie Company | $24.27 | 2023 | Imbruvica, Epkinly |
| Taiho Oncology, INC. | $23.11 | 2023 | |
| Adaptive Biotechnologies Corporation | $21.20 | 2025 | Clonoseq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rizza Macas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.